Rho Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Rho Capital Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-656,948	Closed	-$4.99M	–	4
2017 Q2	$4.99M	Hold	656,948	–	–	6.97%	3
2017 Q1	$5.26M	Hold	656,948	–	–	7.39%	2
2016 Q4	$16M	Hold	656,948	–	–	12.28%	3
2016 Q3	$24.9M	Hold	656,948	–	–	16.83%	4
2016 Q2	$19.6M	Hold	656,948	–	–	15.64%	3
2016 Q1	$19.4M	Hold	656,948	–	–	10.65%	4
2015 Q4	$29.8M	Sell	656,948 -60,698	-8%	-$2.65M	10.24%	4
2015 Q3	$27M	Hold	717,646	–	–	8.96%	5
2015 Q2	$14.1M	Hold	717,646	–	–	4.92%	5
2015 Q1	$15.6M	Buy	+717,646	New	+$16.8M	6.49%	5

Other funds holding RCKT

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rho Capital Partners's RCKT Position: Q3 2017 in Review

Rho Capital Partners sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 656,948 shares — an estimated $4.99M sold.

Rho Capital Partners first reported a position in RCKT in Q1 2015 and held it in 10 quarters. The position peaked at $29.8M in Q4 2015. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

Rho Capital Partners reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Rho Capital Partners sold 656,948 Rocket Pharmaceuticals shares in Q3 2017, an estimated $4.99M.
Rho Capital Partners first reported a position in Rocket Pharmaceuticals in Q1 2015 and held it in 10 quarters.
Rho Capital Partners's Rocket Pharmaceuticals position peaked at $29.8M in Q4 2015.
35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Rho Capital Partners's 13F filing for Q3 2017, filed 6 Nov 2017.